Diacylglycerol kinase α regulates the formation and polarisation of mature multivesicular bodies involved in the secretion of Fas ligand-containing exosomes in T lymphocytes.
Multivesicular bodies (MVBs) are endocytic compartments that contain intraluminal vesicles formed by inward budding from the limiting membrane of endosomes. In T lymphocytes, these vesicles contain pro-apoptotic Fas ligand (FasL), which may be secreted as 'lethal exosomes' upon fusion of MVBs with the plasma membrane. Diacylglycerol kinase α (DGKα) regulate the secretion of exosomes, but it is unclear how this control is mediated. T-lymphocyte activation increases the number of MVBs that contain FasL. DGKα is recruited to MVBs and to exosomes in which it has a double function. DGKα kinase activity exerts a negative role in the formation of mature MVBs, as we demonstrate by the use of an inhibitor. Downmodulation of DGKα protein resulted in inhibition of both the polarisation of MVBs towards immune synapse and exosome secretion. The subcellular location of DGKα together with its complex role in the formation and polarised traffic of MVBs support the notion that DGKα is a key regulator of the polarised secretion of exosomes.
Instituto de Biologia y Genetica Molecular, CSIC-Universidad de Valladolid, Valladolid, Spain.
R
R
Alonso
C
C
Mazzeo
M C
MC
Rodriguez
M
M
Marsh
A
A
Fraile-Ramos
V
V
Calvo
A
A
Avila-Flores
I
I
Merida
M
M
Izquierdo
D002460:Cell Line; D019852:Diacylglycerol Kinase / Q000032:analysis / Q000037:antagonists & inhibitors / Q000378:metabolism*; D055354:Exosomes / Q000378:metabolism*; D053222:Fas Ligand Protein / Q000378:metabolism*; D006801:Humans; D057146:Multivesicular Bodies / Q000378:metabolism / Q000502:physiology*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D013601:T-Lymphocytes / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*
D053222:Fas Ligand Protein; D034741:RNA, Small Interfering; D019852:Diacylglycerol Kinase
J Biol Chem. 1999 Apr 23;274(17):11447-50
10206945
J Cell Sci. 2003 Jan 15;116(Pt 2):401-14
12482925
J Biol Chem. 2002 Aug 30;277(35):32157-64
12065580
J Biol Chem. 2002 Aug 16;277(33):30300-9
12015310
Nat Methods. 2006 Oct;3(10):797-9
16990811
Nat Immunol. 2003 Nov;4(11):1111-20
14566336
Nat Med. 1999 Jan;5(1):90-6
9883845
Nat Immunol. 2002 Feb;3(2):159-68
11812993
Trends Cell Biol. 1999 May;9(5):174-9
10322451
Cell. 1997 Feb 7;88(3):355-65
9039262
Nature. 1990 Nov 1;348(6296):66-9
2234059
EMBO J. 1998 Jun 1;17(11):2982-93
9606181
Nat Immunol. 2009 Jun;10(6):627-35
19430478
J Exp Med. 1995 Dec 1;182(6):1777-83
7500022
J Biol Chem. 2009 May 1;284(18):12110-24
19265192
J Immunol. 1999 Aug 1;163(3):1274-81
10415024
J Cell Sci. 2007 Jan 1;120(Pt 1):191-9
17164290
J Exp Med. 2002 May 20;195(10):1303-16
12021310
Mol Biol Cell. 2004 Jun;15(6):2932-42
15064353
Nature. 1995 Feb 2;373(6513):385-6
7530334
Science. 2002 Jan 11;295(5553):325-8
11729268
J Immunol. 2001 Dec 15;167(12):6736-44
11739488
Nature. 1998 Mar 12;392(6672):193-7
9515966
Biochimie. 2007 Feb;89(2):213-21
16989932
Traffic. 2002 May;3(5):321-30
11967126
J Cell Biol. 2001 Apr 2;153(1):207-20
11285286
Mol Biol Cell. 2000 Jan;11(1):227-39
10637304
J Biol Chem. 2005 Aug 5;280(31):28439-50
15870081
Science. 2004 Jan 23;303(5657):531-4
14739459
Biochem Pharmacol. 2000 Apr 1;59(7):763-72
10718334
Nat Rev Mol Cell Biol. 2001 Jul;2(7):504-13
11433364
Traffic. 2005 Jan;6(1):2-9
15569240
J Biol Chem. 2003 Apr 18;278(16):14134-45
12571238
J Biol Chem. 2003 Oct 3;278(40):38786-95
12878588
J Immunol. 1996 Jul 1;157(1):21-8
8683117